Analyst Ratings For Vectura Group PLC (LON:VEC)
Today, Numis Securities Ltd reiterated its Buy rating on Vectura Group PLC (LON:VEC) with a price target of GBX 252.
There are 8 buy ratings on the stock.
The current consensus rating on Vectura Group PLC (LON:VEC) is Buy (Score: 3.00) with a consensus target price of GBX 220.50 per share, a potential .
Some recent analyst ratings include
- 2/16/2017-Numis Securities Ltd Reiterated Rating of Buy.
- 2/16/2017-Peel Hunt Reiterated Rating of Buy.
- 1/24/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 1/17/2017-J P Morgan Chase & Co Reiterated Rating of Overweight.
- 1/11/2017-N+1 Singer Reiterated Rating of Buy.
- 11/29/2016-FinnCap Reiterated Rating of Buy.
- 7/28/2016-Citigroup Inc. Reiterated Rating of Buy.
About Vectura Group PLC (LON:VEC)
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Recent Trading Activity for Vectura Group PLC (LON:VEC)
Shares of Vectura Group PLC closed the previous trading session at 143.68 up +2.08 1.47% with 1,005,639 shares trading hands.
